The DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.
Prognostic and Predictive Biomarkers in Gliomas
Open accessAbstract
Gliomas are the most common central nervous system tumors. New technologies, including genetic research and advanced statistical methods, revolutionize the therapeutic approach to the patient and reveal new points of treatment options. Moreover, the 2021 World Health Organization Classification of Tumors of the Central Nervous System has fundamentally changed the classification of gliomas and incorporated many molecular biomarkers. Given the rapid progress in neuro-oncology, here we compile the latest research on prognostic and predictive biomarkers in gliomas. In adult patients, IDH mutations are positive prognostic markers and have the greatest prognostic significance. However, CDKN2A deletion, in IDH-mutant astrocytomas, is a marker of the highest malignancy grade. Moreover, the presence of TERT promoter mutations, EGFR alterations, or a combination of chromosome 7 gain and 10 loss upgrade IDH-wildtype astrocytoma to glioblastoma. In pediatric patients, H3F3A alterations are the most important markers which predict the worse outcome. MGMT promoter methylation has the greatest clinical significance in predicting responses to temozolomide (TMZ). Conversely, mismatch repair defects cause hypermutation phenotype predicting poor response to TMZ. Finally, we discussed liquid biopsies, which are promising diagnostic, prognostic, and predictive techniques, but further work is needed to implement these novel technologies in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
The widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Nagrath, S., Sequist, L. V., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., Smith, M. R., Kwak, E. L., Digumarthy, S., Muzikansky, A., et al. (2007) · Nature · doi:10.1038/nature06385 · Cited by 3,559
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
lincRNAs: Genomics, Evolution, and Mechanisms
Ulitsky, I., & Bartel, D. P. (2013) · Cell · doi:10.1016/j.cell.2013.06.020 · Cited by 2,608
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
The epidemiology of glioma in adults: a "state of the science" review
Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, M., Schwartzbaum, J. A., Turner, M. C., Walsh, K. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou087 · Cited by 2,220
de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Glioma Groups Based on 1p/19q,IDH, and TERT Promoter Mutations in Tumors
Eckel-Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M. L., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,982
Management of glioblastoma: State of the art and future directions
Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21613 · Cited by 1,972
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,908
Cohen, S. J., Punt, C. J. A., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E., Miller, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8923 · Cited by 1,841
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Huang, F. W., Hodis, E., Xu, M. J., Kryukov, G. V., Chin, L., & Garraway, L. A. (2013) · Science · doi:10.1126/science.1229259 · Cited by 1,816
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,286
EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research
EV-TRACK Consortium, Van Deun, J., Mestdagh, P., Agostinis, P., Akay, Ö., Anand, S., Anckaert, J., Martinez, Z. A., Baetens, T., Beghein, E., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4185 · Cited by 1,284
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,135
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Brandsma, D., Stalpers, L., Taal, W., Sminia, P., & van den Bent, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70125-6 · Cited by 1,121
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Extensive modulation of a set of microRNAs in primary glioblastoma
Ciafrè, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C.-G., Sabatino, G., Negrini, M., Maira, G., Croce, C. M., & Farace, M. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.030 · Cited by 1,096
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
Khuong-Quang, D.-A., Buczkowicz, P., Rakopoulos, P., Liu, X.-Y., Fontebasso, A. M., Bouffet, E., Bartels, U., Albrecht, S., Schwartzentruber, J., Letourneau, L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0998-0 · Cited by 1,028
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,027
Epidemiology and molecular pathology of glioma
Schwartzbaum, J. A., Fisher, J. L., Aldape, K. D., & Wrensch, M. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0289 · Cited by 949
Brat, D. J., Aldape, K., Colman, H., Holland, E. C., Louis, D. N., Jenkins, R. B., Kleinschmidt-DeMasters, B. K., Perry, A., Reifenberger, G., Stupp, R., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1913-0 · Cited by 896
Histone variants — ancient wrap artists of the epigenome
Talbert, P. B., & Henikoff, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2861 · Cited by 844
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812
Jenkins, R. B., Blair, H., Ballman, K. V., Giannini, C., Arusell, R. M., Law, M., Flynn, H., Passe, S., Felten, S., Brown, P. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1796 · Cited by 763
Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperierre, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3414 · Cited by 728
Genetic and molecular epidemiology of adult diffuse glioma
Molinaro, A. M., Taylor, J. W., Wiencke, J. K., & Wrensch, M. R. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0220-2 · Cited by 709
Mechanisms and therapeutic implications of hypermutation in gliomas
Touat, M., Li, Y. Y., Boynton, A. N., Spurr, L. F., Iorgulescu, J. B., Bohrson, C. L., Cortes-Ciriano, I., Birzu, C., Geduldig, J. E., Pelton, K., et al. (2020) · Nature · doi:10.1038/s41586-020-2209-9 · Cited by 677
First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
Lemery, S., Keegan, P., & Pazdur, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1709968 · Cited by 664
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., et al. (2003) · PubMed · Cited by 663
Stupp, R., Taillibert, S., Kanner, A. A., Read, W. L., Steinberg, D. M., Lhermitte, B., Toms, S. A., Idbaïh, A., Ahluwalia, M. S., Fink, K., et al. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · doi:10.5167/uzh-143757 · Cited by 630
Lovejoy, C. A., Li, W., Reisenweber, S., Thongthip, S., Bruno, J., de Lange, T., De, S., Petrini, J. H. J., Sung, P. A., Jasin, M., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002772 · Cited by 629
IDH1 and IDH2 mutations in gliomas
Cohen, A. L., Holmen, S. L., & Colman, H. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0345-4 · Cited by 629
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid
Miller, A. M., Shah, R. H., Pentsova, E. I., Pourmaleki, M., Briggs, S., Distefano, N., Zheng, Y., Skakodub, A., Mehta, S. A., Campos, C., et al. (2019) · Nature · doi:10.1038/s41586-019-0882-3 · Cited by 628
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Ichimura, K., Pearson, D. M., Kocialkowski, S., Bäcklund, L. M., Chan, R., Jones, D. T. W., & Collins, V. P. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-025 · Cited by 595
Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, B. A., Heaphy, C. M., de Wilde, R. F., Rodriguez, F. J., Rosemberg, S., Oba-Shinjo, S. M., Nagahashi Marie, S. K., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.588 · Cited by 584
Next-generation sequencing in liquid biopsy: cancer screening and early detection
Chen, M., & Zhao, H. (2019) · Human Genomics · doi:10.1186/s40246-019-0220-8 · Cited by 556
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7961 · Cited by 542
The biology of circulating tumor cells
Pantel, K., & Speicher, M. R. (2016) · Oncogene · doi:10.1038/onc.2015.192 · Cited by 539
McNeill, K. A. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.06.014 · Cited by 531
Louis, D. N., Wesseling, P., Aldape, K., Brat, D. J., Capper, D., Cree, I. A., Eberhart, C., Figarella‐Branger, D., Fouladi, M., Fuller, G. N., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12832 · Cited by 525
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
Brat, D. J., Aldape, K., Colman, H., Figrarella-Branger, D., Fuller, G. N., Giannini, C., Holland, E. C., Jenkins, R. B., Kleinschmidt-DeMasters, B., Komori, T., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02127-9 · Cited by 520
Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase
Pegg, A. E., Dolan, M. E., & Moschel, R. C. (1995) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(08)60879-x · Cited by 506
IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Yang, H., Ye, D., Guan, K.-L., & Xiong, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1773 · Cited by 458
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas
Shirahata, M., Ono, T., Stichel, D., Schrimpf, D., Reuss, D. E., Sahm, F., Koelsche, C., Wefers, A., Reinhardt, A., Huang, K., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1849-4 · Cited by 457
Reuss, D. E., Sahm, F., Schrimpf, D., Wiestler, B., Capper, D., Koelsche, C., Schweizer, L., Korshunov, A., Jones, D. T. W., Hovestadt, V., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1370-3 · Cited by 449
Liu, X.-Y., Gerges, N., Korshunov, A., Sabha, N., Khuong-Quang, D.-A., Fontebasso, A. M., Fleming, A., Hadjadj, D., Schwartzentruber, J., Majewski, J., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1031-3 · Cited by 428
Blood platelets contain tumor-derived RNA biomarkers
Nilsson, R. J. A., Balaj, L., Hulleman, E., van Rijn, S., Pegtel, D. M., Walraven, M., Widmark, A., Gerritsen, W. R., Verheul, H. M., Vandertop, W. P., et al. (2011) · Blood · doi:10.1182/blood-2011-03-344408 · Cited by 399
The EGFRvIII variant in glioblastoma multiforme
Gan, H. K., Kaye, A. H., & Luwor, R. B. (2009) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2008.12.005 · Cited by 396
New insights into long noncoding RNAs and their roles in glioma
Peng, Z., Liu, C., & Wu, M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0812-2 · Cited by 378
Arita, H., Narita, Y., Fukushima, S., Tateishi, K., Matsushita, Y., Yoshida, A., Miyakita, Y., Ohno, M., Collins, V. P., Kawahara, N., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1141-6 · Cited by 376
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
de Wit, M. C. Y., de Bruin, H. G., Eijkenboom, W., Sillevis Smitt, P. A. E., & van den Bent, M. J. (2004) · Neurology · doi:10.1212/01.wnl.0000133398.11870.9a · Cited by 357
Consensus guidelines for lumbar puncture in patients with neurological diseases
Engelborghs, S., Niemantsverdriet, E., Struyfs, H., Blennow, K., Brouns, R., Comabella, M., Dujmovic, I., van der Flier, W., Frölich, L., Galimberti, D., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.04.007 · Cited by 355
Korshunov, A., Ryzhova, M., Hovestadt, V., Bender, S., Sturm, D., Capper, D., Meyer, J., Schrimpf, D., Kool, M., Northcott, P. A., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1405-4 · Cited by 350
Shi, L., Chen, J., Yang, J., Pan, T., Zhang, S., & Wang, Z. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.009 · Cited by 343
Long non-coding RNA expression profiles predict clinical phenotypes in glioma
Zhang, X., Sun, S., Pu, J. K. S., Tsang, A. C. O., Lee, D., Man, V. O. Y., Lui, W. M., Wong, S. T. S., & Leung, G. K. K. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.06.004 · Cited by 341
Mansouri, A., Hachem, L. D., Mansouri, S., Nassiri, F., Laperriere, N. J., Xia, D., Lindeman, N. I., Wen, P. Y., Chakravarti, A., Mehta, M. P., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noy132 · Cited by 340
Hematogenous dissemination of glioblastoma multiforme
Müller, C., Holtschmidt, J., Auer, M., Heitzer, E., Lamszus, K., Schulte, A., Matschke, J., Langer-Freitag, S., Gasch, C., Stoupiec, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009095 · Cited by 328
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
JIAPAER, S., FURUTA, T., TANAKA, S., KITABAYASHI, T., & NAKADA, M. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0141 · Cited by 324
Pekmezci, M., Rice, T., Molinaro, A. M., Walsh, K. M., Decker, P. A., Hansen, H., Sicotte, H., Kollmeyer, T. M., McCoy, L. S., Sarkar, G., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1690-1 · Cited by 319
Stichel, D., Ebrahimi, A., Reuss, D., Schrimpf, D., Ono, T., Shirahata, M., Reifenberger, G., Weller, M., Hänggi, D., Wick, W., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1905-0 · Cited by 313
Bleeker, F. E., Atai, N. A., Lamba, S., Jonker, A., Rijkeboer, D., Bosch, K. S., Tigchelaar, W., Troost, D., Vandertop, W. P., Bardelli, A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0645-6 · Cited by 302
Teplyuk, N. M., Mollenhauer, B., Gabriely, G., Giese, A., Kim, E., Smolsky, M., Kim, R. Y., Saria, M. G., Pastorino, S., Kesari, S., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos074 · Cited by 302
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
Box, P. (2005) · Dkgest of the World Latest Medical Information · Cited by 299
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma
SongTao, Q., Lei, Y., Si, G., YanQing, D., HuiXia, H., XueLin, Z., LanXiao, W., & Fei, Y. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2011.02134.x · Cited by 294
Metellus, P., Coulibaly, B., Colin, C., de Paula, A. M., Vasiljevic, A., Taieb, D., Barlier, A., Boisselier, B., Mokhtari, K., Wang, X. W., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0777-8 · Cited by 289
Reinhardt, A., Stichel, D., Schrimpf, D., Sahm, F., Korshunov, A., Reuss, D. E., Koelsche, C., Huang, K., Wefers, A. K., Hovestadt, V., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1837-8 · Cited by 289
Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome
Kaloshi, G., Benouaich-Amiel, A., Diakite, F., Taillibert, S., Lejeune, J., Laigle-Donadey, F., Renard, M.-A., Iraqi, W., Idbaih, A., Paris, S., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000262034.26310.a2 · Cited by 286
Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kannan, K., Inagaki, A., Silber, J., Gorovets, D., Zhang, J., Kastenhuber, E. R., Heguy, A., Petrini, J. H., Chan, T. A., & Huse, J. T. (2012) · Oncotarget · doi:10.18632/oncotarget.689 · Cited by 278
Møller, H. G., Rasmussen, A. P., Andersen, H. H., Johnsen, K. B., Henriksen, M., & Duroux, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8349-7 · Cited by 266
Human Glioma Growth Is Controlled by MicroRNA-10b
Gabriely, G., Yi, M., Narayan, R. S., Niers, J. M., Wurdinger, T., Imitola, J., Ligon, K. L., Kesari, S., Esau, C., Stephens, R. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3568 · Cited by 266
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
Labussière, M., Idbaih, A., Wang, X.-W., Marie, Y., Boisselier, B., Falet, C., Paris, S., Laffaire, J., Carpentier, C., Crinière, E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cf3a · Cited by 260
Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
Sullivan, J. P., Nahed, B. V., Madden, M. W., Oliveira, S. M., Springer, S., Bhere, D., Chi, A. S., Wakimoto, H., Rothenberg, S. M., Sequist, L. V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0471 · Cited by 255
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Reifenberger, G., Hentschel, B., Felsberg, J., Schackert, G., Simon, M., Schnell, O., Westphal, M., Wick, W., Pietsch, T., Loeffler, M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27385 · Cited by 252
Arita, H., Yamasaki, K., Matsushita, Y., Nakamura, T., Shimokawa, A., Takami, H., Tanaka, S., Mukasa, A., Shirahata, M., Shimizu, S., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0351-2 · Cited by 252
Circulating biomarkers in patients with glioblastoma
Müller Bark, J., Kulasinghe, A., Chua, B., Day, B. W., & Punyadeera, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0603-6 · Cited by 252
Ellison, D. W., Hawkins, C., Jones, D. T. W., Onar-Thomas, A., Pfister, S. M., Reifenberger, G., & Louis, D. N. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01987-0 · Cited by 247
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas
Simon, M., Hosen, I., Gousias, K., Rachakonda, S., Heidenreich, B., Gessi, M., Schramm, J., Hemminki, K., Waha, A., & Kumar, R. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou158 · Cited by 237
miR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumors
Conti, A., Aguennouz, M., La Torre, D., Tomasello, C., Cardali, S., Angileri, F. F., Maio, F., Cama, A., Germanò, A., Vita, G., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9797-4 · Cited by 229
Vaubel, R. A., Tian, S., Remonde, D., Schroeder, M. A., Mladek, A. C., Kitange, G. J., Caron, A., Kollmeyer, T. M., Grove, R., Peng, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0909 · Cited by 227
MAPK pathway activation in pilocytic astrocytoma
Jones, D. T. W., Gronych, J., Lichter, P., Witt, O., & Pfister, S. M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0898-9 · Cited by 225
Guidelines for human gene nomenclature
Bruford, E. A., Braschi, B., Denny, P., Jones, T. E. M., Seal, R. L., & Tweedie, S. (2020) · Nature Genetics · doi:10.1038/s41588-020-0669-3 · Cited by 218
Combined analysis of TERT , EGFR , and IDH status defines distinct prognostic glioblastoma classes
Labussière, M., Boisselier, B., Mokhtari, K., Di Stefano, A.-L., Rahimian, A., Rossetto, M., Ciccarino, P., Saulnier, O., Paterra, R., Marie, Y., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000814 · Cited by 218
Tumor Treating Fields Perturb the Localization of Septins and Cause Aberrant Mitotic Exit
Gera, N., Yang, A., Holtzman, T. S., Lee, S. X., Wong, E. T., & Swanson, K. D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125269 · Cited by 217
Temozolomide-associated hypermutation in gliomas
Choi, S., Yu, Y., Grimmer, M. R., Wahl, M., Chang, S. M., & Costello, J. F. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy016 · Cited by 214
Adult IDH wild-type lower-grade gliomas should be further stratified
Aibaidula, A., Chan, A. K.-Y., Shi, Z., Li, Y., Zhang, R., Yang, R., Li, K. K.-W., Chung, N. Y.-F., Yao, Y., Zhou, L., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox078 · Cited by 213
A Ten-microRNA Expression Signature Predicts Survival in Glioblastoma
Srinivasan, S., Patric, I. R. P., & Somasundaram, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017438 · Cited by 207
Molenaar, R. J., Verbaan, D., Lamba, S., Zanon, C., Jeuken, J. W. M., Boots-Sprenger, S. H. E., Wesseling, P., Hulsebos, T. J. M., Troost, D., van Tilborg, A. A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou005 · Cited by 207
The emerging role of exosome-derived non-coding RNAs in cancer biology
Fan, Q., Yang, L., Zhang, X., Peng, X., Wei, S., Su, D., Zhai, Z., Hua, X., & Li, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.10.040 · Cited by 204
Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma
Wang, Q., Li, P., Li, A., Jiang, W., Wang, H., Wang, J., & Xie, K. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-97 · Cited by 202
Weller, M., Stupp, R., Hegi, M. E., van den Bent, M., Tonn, J. C., Sanson, M., Wick, W., & Reifenberger, G. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos206 · Cited by 202
A specific miRNA signature in the peripheral blood of glioblastoma patients
Roth, P., Wischhusen, J., Happold, C., Chandran, P. A., Hofer, S., Eisele, G., Weller, M., & Keller, A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07307.x · Cited by 200
An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme
Zhou, M., Zhang, Z., Zhao, H., Bao, S., Cheng, L., & Sun, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0572-9 · Cited by 200
Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma
Baraniskin, A., Kuhnhenn, J., Schlegel, U., Maghnouj, A., Zollner, H., Schmiegel, W., Hahn, S., & Schroers, R. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor169 · Cited by 198
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression
Zhang, W., Zhang, J., Hoadley, K., Kushwaha, D., Ramakrishnan, V., Li, S., Kang, C., You, Y., Jiang, C., Song, S. W., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos089 · Cited by 196
ctDNA monitoring using patient-specific sequencing and integration of variant reads
Wan, J. C. M., Heider, K., Gale, D., Murphy, S., Fisher, E., Mouliere, F., Ruiz-Valdepenas, A., Santonja, A., Morris, J., Chandrananda, D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8084 · Cited by 194
Hormigo, A., Gu, B., Karimi, S., Riedel, E., Panageas, K. S., Edgar, M. A., Tanwar, M. K., Rao, J. S., Fleisher, M., DeAngelis, L. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0181 · Cited by 182
Circulating biomarkers for gliomas
Westphal, M., & Lamszus, K. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.171 · Cited by 181
Piccioni, D. E., Achrol, A. S., Kiedrowski, L. A., Banks, K. C., Boucher, N., Barkhoudarian, G., Kelly, D. F., Juarez, T., Lanman, R. B., Raymond, V. M., et al. (2019) · CNS Oncology · doi:10.2217/cns-2018-0015 · Cited by 170
Gwak, H., Kim, T. H., Jo, G. H., Kim, Y., Kwak, H., Kim, J. H., Yin, J., Yoo, H., Lee, S. H., & Park, J. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047449 · Cited by 168
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
Thon, N., Kreth, S., & Kreth, F. W. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s50208 · Cited by 166
miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients
Akers, J. C., Ramakrishnan, V., Kim, R., Phillips, S., Kaimal, V., Mao, Y. Q., Hua, W., Yang, I., Fu, C.-C., Nolan, J. P., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1784-3 · Cited by 165
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
Yang, P., Zhang, W., Wang, Y., Peng, X., Chen, B., Qiu, X., Li, G., Li, S., Wu, C., Yao, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5683 · Cited by 162
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
Aslan, K., Turco, V., Blobner, J., Sonner, J. K., Liuzzi, A. R., Núñez, N. G., De Feo, D., Kickingereder, P., Fischer, M., Green, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14642-0 · Cited by 162
MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta‐analysis
Zhou, Q., Liu, J., Quan, J., Liu, W., Tan, H., & Li, W. (2018) · Cancer Science · doi:10.1111/cas.13714 · Cited by 160
Lu, V. M., O’Connor, K. P., Shah, A. H., Eichberg, D. G., Luther, E., Komotar, R. J., & Ivan, M. E. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03528-2 · Cited by 157
Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
Daniel, P. M., Sabri, S., Chaddad, A., Meehan, B., Jean‐Claude, B. J., Rak, J. W., & Abdulkarim, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00041 · Cited by 155
Mancini, A., Xavier‐Magalhães, A., Woods, W. S., Nguyen, K.-T., Amen, A. M., Hayes, J. L., Fellmann, C., Gapinske, M., McKinney, A., Hong, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.003 · Cited by 149
TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma
Mosrati, M. A., Malmström, A., Łysiak, M., Krysztofiak, A., Hallbeck, M., Milos, P., Hallbeck, A., Bratthäll, C., Strandéus, M., Stenmark‐Askmalm, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4389 · Cited by 145
Hamisch, C., Kickingereder, P., Fischer, M., Simon, T., & Ruge, M. I. (2017) · Journal of Neurosurgery Pediatrics · doi:10.3171/2017.2.peds1665 · Cited by 144
Spiegl‐Kreinecker, S., Lötsch, D., Ghanim, B., Pirker, C., Mohr, T. T., Laaber, M., Weis, S., Olschowski, A., Webersinke, G., Pichler, J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov010 · Cited by 140
Keller, S., & Schmidt, M. H. H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061295 · Cited by 139
Tumor treating fields increases membrane permeability in glioblastoma cells
Chang, E., Patel, C. B., Pohling, C., Young, C., Song, J., Flores, T. A., Zeng, Y., Joubert, L.-M., Arami, H., Natarajan, A., et al. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0130-x · Cited by 137
A cerebrospinal fluid microRNA signature as biomarker for glioblastoma
Akers, J. C., Hua, W., Li, H., Ramakrishnan, V., Yang, Z., Quan, K., Zhu, W. P., Li, J., Figueroa, J. M., Hirshman, B. R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18332 · Cited by 137
Shi, L. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1179 · Cited by 135
Zou, P., Xu, H., Chen, P., Yan, Q., Zhao, L., Zhao, P., & Gu, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068782 · Cited by 133
2-Hydroxyglutarate in Cancer Cells
Ježek, P. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130
Eskilsson, E., Røsland, G. V., Talasila, K. M., Knappskog, S., Keunen, O., Sottoriva, A., Foerster, S., Solecki, G. M., Taxt, T., Jiřík, R., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now113 · Cited by 127
Yang, R. R., Shi, Z., Zhang, Z., Chan, A. K., Aibaidula, A., Wang, W., Kwan, J. S. H., Poon, W. S., Chen, H., Li, W., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12801 · Cited by 127
The Roles of miRNA in Glioblastoma Tumor Cell Communication: Diplomatic and Aggressive Negotiations
Buruiană, A., Florian, I. Ş., Florian, I. A., Timiș, T. L., Mihu, C. M., Miclăuș, M., Oșan, S., Hrapșa, I., Cataniciu, R. C., Farcas, M. F., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061950 · Cited by 127
Appay, R., Dehais, C., Colin, C., Alentorn, A., Carpentier, C., Ducray, F., Ibdaih, A., Kamoun, A., Mokhtari, K., Tabouret, E., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz126.000 · Cited by 126
Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma
Yang, J., Yang, J., Tong, J., Jing, S., Fan, B., Wang, F., Sun, G., & Jiao, B. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2308-5 · Cited by 124
Ryall, S. T., Krishnatry, R., Arnoldo, A., Buczkowicz, P., Mistry, M., Siddaway, R., Ling, C., Pajovic, S., Yu, M., Rubin, J. B., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0353-0 · Cited by 121
Circulating Glioma Cells Exhibit Stem Cell-like Properties
Liu, T., Xu, H., Huang, M., Ma, W., Saxena, D., Lustig, R. A., Alonso‐Basanta, M., Zhang, Z., O’Rourke, D. M., Zhang, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0650 · Cited by 120
An autophagy‐related long non‐coding RNA signature for glioma
Luan, F., Chen, W., Chen, M., Yan, J., Chen, H., Yu, H., Liu, T., & Mo, L. (2019) · FEBS Open Bio · doi:10.1002/2211-5463.12601 · Cited by 119
Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma
Hu, X., Martínez-Ledesma, E., Zheng, S., Kim, H., Barthel, F. P., Jiang, T., Hess, K. R., & Verhaak, R. G. W. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now285 · Cited by 116
Boots‐Sprenger, S., Sijben, A. E. J., Rijntjes, J., Tops, B. B. J., Idema, A. J. S., Rivera, A. L., Bleeker, F. E., Gijtenbeek, A., Alfaro-Munoz, K. D., Heathcock, L. E., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2012.166 · Cited by 113
Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?
Tom, M. C., Cahill, D. P., Buckner, J. C., Dietrich, J., Parsons, M. W., & Yu, J. S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238353 · Cited by 113
Suwala, A. K., Stichel, D., Schrimpf, D., Kloor, M., Wefers, A. K., Reinhardt, A., Maas, S. L. N., Kratz, C. P., Schweizer, L., Hasselblatt, M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02243-6 · Cited by 113
Shah, N., Lin, B., Sibenaller, Z. A., Ryken, T. C., Lee, H., Yoon, J., Rostad, S. W., & Foltz, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016146 · Cited by 112
The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis
Zhang, K., Wang, X., Zhou, B., & Zhang, L. (2013) · Familial Cancer · doi:10.1007/s10689-013-9607-1 · Cited by 111
Erdem‐Eraslan, L., Gravendeel, L. A. M., de Rooi, J., Eilers, P. H. C., Idbaïh, A., Spliet, W. G. M., den Dunnen, W. F. A., Teepen, J. L. J. M., Wesseling, P., Smitt, P. A. E. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1444 · Cited by 110
Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I–III
Visani, M., de Biase, D., Marucci, G., Cerasoli, S., Nigrisoli, E., Reggiani, M. L. B., Albani, F., Baruzzi, A., Pession, A., & the PERNO study group (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.010 · Cited by 108
Comprehensive analysis of microRNA expression profile in malignant glioma tissues
Piwecka, M., Rolle, K., Belter, A., Barciszewska, A. M., Żywicki, M., Michalak, M., Nowak, S., Naskręt-Barciszewska, M. Z., & Barciszewski, J. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.03.007 · Cited by 108
miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients
Dong, L., Li, Y., Han, C., Wang, X., She, L., & Zhang, H. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2459 · Cited by 107
Liquid biopsies in patients with diffuse glioma
Best, M. G., Sol, N., Zijl, S., Reijneveld, J. C., Wesseling, P., & Würdinger, T. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1399-y · Cited by 104
Huse, J. T., Diamond, E. L., Wang, L., & Rosenblum, M. K. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1359-y · Cited by 102
Wood, M. D., Tihan, T., Perry, A., Chacko, G., Turner, C. P., Pu, C., Payne, C., Yu, A. K.-T., Bannykh, S., & Solomon, D. A. (2017) · Brain Pathology · doi:10.1111/bpa.12561 · Cited by 100
Temozolomide affects Extracellular Vesicles Released by Glioblastoma Cells
André‐Grégoire, G., Bidère, N., & Gavard, J. (2018) · Biochimie · doi:10.1016/j.biochi.2018.02.007 · Cited by 98
Blood-based biomarkers for the diagnosis and monitoring of gliomas
Zachariah, M. A., Oliveira–Costa, J. P., Carter, B. S., Stott, S. L., & Nahed, B. V. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy074 · Cited by 97
Mair, R. J., Mouliere, F. C., Smith, C. G., Chandrananda, D., Gale, D. G., Marass, F., Tsui, D. W. Y., Massie, C. E., Wright, A. J., Watts, C., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0074 · Cited by 97
Prognostic and Predictive Epigenetic Biomarkers in Oncology
Kaminska, K. H., Nalejska, E., Kubiak, M., Wojtysiak, J., Żołna, Ł., Kowalewski, J., & Lewandowska, M. A. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0371-7 · Cited by 97
Self-citationSabha, N., Knobbe-Thomsen, C. B., Maganti, M. D., Omar, S. A., Bernstein, M., Cairns, R. A., Çako, B., von Deimling, A., Capper, D., Mak, T. W., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not299 · Cited by 94
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
Wang, H., Tang, K., Liang, T., Zhang, W., Li, J.-Y., Wang, W., Hu, H., Li, M., Wang, H., He, X.-Z., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0362-7 · Cited by 94
Gliomas Interact with Non-glioma Brain Cells via Extracellular Vesicles
Gao, X., Zhang, Z., Mashimo, T., Shen, B., Nyagilo, J. O., Wang, H., Wang, Y., Liu, Z., Mulgaonkar, A., Hu, X.-L., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.089 · Cited by 93
Nguyen, H. N., Lie, A., Li, T., Chowdhury, R., Liu, F., Ozer, B. H., Wei, B., Green, R. M., Ellingson, B. M., Wang, H.-J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now189 · Cited by 91
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
IWAMOTO, F. M., Hottinger, A. F., Karimi, S., Riedel, E., Dantis, J., Jahdi, M., Panageas, K., Lassman, A. B., Abrey, L. E., Fleisher, M., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor117 · Cited by 89
Evaluation of serum extracellular vesicles as noninvasive diagnostic markers of glioma
Wang, H., Jiang, D., Li, W., Xiang, X., Zhao, J., Yu, B., Wang, C., He, Z., Zhu, L., & Yang, Y. (2019) · Theranostics · doi:10.7150/thno.33114 · Cited by 88
Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
Chai, R., Li, G., Liu, Y., Zhang, K., Zhao, Z., Wu, F., Chang, Y., Pang, B., Li, J., Li, Y., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0179 · Cited by 87
Role of extracellular vesicles in glioma progression
Quezada, C., Torres, Á., Niechi, I., Uribe, D., Contreras‐Duarte, S., Toledo, F., Martín, R. S., Gutiérrez, J., & Sobrevía, L. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.12.003 · Cited by 85
A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration
Chiang, J., Harreld, J. H., Tinkle, C. L., Moreira, D. C., Li, X., Acharya, S., Qaddoumi, I. A., & Ellison, D. W. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02081-1 · Cited by 85
Vogazianou, A. P., Chan, R., Bäcklund, L. M., Pearson, D. M., Liu, L., Langford, C. F., Gregory, S. G., Collins, V. P., & Ichimura, K. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop075 · Cited by 84
Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis
Sun, H., Yin, L.-H., Li, S., Han, S., Song, G., Liu, N., & Yan, C. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1107-5 · Cited by 83
Survival of European patients with central nervous system tumors
Sant, M., Minicozzi, P., Lagorio, S., Johannesen, T. B., Marcos‐Gragera, R., Francisci, S., & the EUROCARE Working Group (2011) · International Journal of Cancer · doi:10.1002/ijc.26335 · Cited by 83
The discovery of colchicine-SAHA hybrids as a new class of antitumor agents
Zhang, X., Zhang, J., Tong, L., Luo, Y., Su, M., Zang, Y., Li, J. X., Lu, W. P., & Chen, Y. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.03.049 · Cited by 82
Glioblastoma: To Target the Tumor Cell or the Microenvironment?
Vleeschouwer, S. D., & Bergers, G. (2017) · Codon Publications eBooks · doi:10.15586/codon.glioblastoma.2017.ch16 · Cited by 82
Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
Radke, J., Koch, A., Pritsch, F., Schumann, E., Misch, M., Hempt, C., Lenz, K., Loebel, F., Paschereit, F., Heppner, F. L., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0745-z · Cited by 81
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
Heredia-Soto, V., Rodríguez-Salas, N., & Feliú, J. (2021) · Cancers · doi:10.3390/cancers13081986 · Cited by 81
Plasma miR-221/222 Family as Novel Descriptive and Prognostic Biomarkers for Glioma
Zhang, R., Pang, B., Xin, T., Guo, H., Xing, Y., Xu, S., Feng, B., Liu, B., & Pang, Q. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-9079-9 · Cited by 80
Myb proteins: angels and demons in normal and transformed cells
Zhou, Y. E. (2010) · Frontiers in bioscience · doi:10.2741/3738 · Cited by 80
Emerging circulating biomarkers in glioblastoma: promises and challenges
Touat, M., Durán-Peña, A., Alentorn, A., Lacroix, L., Massard, C., & Idbaïh, A. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1087315 · Cited by 79
Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma
Chinnaiyan, P., Chowdhary, S. A., Potthast, L., Prabhu, A. H., Tsai, Y.-Y., Sarcar, B., Kahali, S., Brem, S. S., Yu, H. M., Rojiani, A. M., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor187 · Cited by 74
Extracellular Vesicles in Glioma: From Diagnosis to Therapy
Basu, B., & Ghosh, M. K. (2019) · BioEssays · doi:10.1002/bies.201800245 · Cited by 72
Serum MicroRNA-125b as a Potential Biomarker for Glioma Diagnosis
Wei, X., Chen, D., Lv, T., Li, G., & Qu, S. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8993-1 · Cited by 71
Vuong, H. G., Altibi, A. M. A., Duong, U. N. P., Ngo, H. T. T., Pham, T. Q., Chan, A. K., Park, C., Fung, K.-M. A., & Hassell, L. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.013 · Cited by 68
Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein
Bang-Christensen, S. R., Pedersen, R. S., Pereira, M. A., Clausen, T. M., Løppke, C., Sand, N. T., Ahrens, T. D., Jørgensen, A. M., Lim, Y. C., Goksøyr, L., et al. (2019) · Cells · doi:10.3390/cells8090998 · Cited by 68
Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas
Balesaria, S., Brock, C., Bower, M., Clark, J., Nicholson, S., Lewis, P. D., de Sanctis, S., Evans, H. S., Peterson, D., Mendoza, N., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6693403 · Cited by 67
Reis (2010) · Oncology Reports · doi:10.3892/or_00000808 · Cited by 66
Gene Expression Integration into Pathway Modules Reveals a Pan-Cancer Metabolic Landscape
Çubuk, C., Hidalgo, M. R., Amadoz, A., Pujana, M. Á., Mateo, F., Herranz, C., Carbonell‐Caballero, J., & Dopazo, J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2705 · Cited by 66
Tabouret, É., Boudouresque, F., Barrié, M., Matta, M., Boucard, C., Loundou, A., Carpentier, A., Sanson, M., Métellus, P., Figarella‐Branger, D., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not226 · Cited by 65
Ma, S., Rudra, S. F., Campian, J. L., Dahiya, S. M., Dunn, G. P., Johanns, T. M., Goldstein, M., Kim, A. H., & Huang, J. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa126 · Cited by 64
Figarella-Branger, D., Mokhtari, K., Dehais, C., Jouvet, A., Uro-Coste, E., Colin, C., Carpentier, C., Forest, F., Maurage, C.-A., Vignaud, J.-M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou047 · Cited by 63
Siegal, T., Charbit, H., Paldor, I., Zelikovitch, B., Canello, T., Benis, A., Wong, M. L., Morokoff, A. P., Kaye, A. H., & Lavon, I. (2016) · Journal of neurosurgery · doi:10.3171/2015.8.jns15437 · Cited by 61
Identification of microRNAs associated with glioma diagnosis and prognosis
Ye, X., Wei, W., Zhang, Z., He, C., Yang, R., Zhang, J., Wu, Z., Huang, Q., & Jiang, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.14445 · Cited by 58
Hao, Z., & Guo, D. (2019) · BMC Cancer · doi:10.1186/s12885-019-6384-8 · Cited by 58
Cited by
Khalighi, S., Reddy, K., Midya, A., Pandav, K. B., Madabhushi, A., & Abedalthagafi, M. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00575-0 · Cited by 306
Bian, Z., Fan, R., & Xie, L. (2022) · Genes · doi:10.3390/genes13050851 · Cited by 302
Metadata
- Authors
- Śledzińska, P., Bebyn, M. G., Furtak, J., Kowalewski, J., & Lewandowska, M. A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-09-26
- Volume
- 22
- Issue
- 19
- Pages
- 10373
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3203918618
- Cited by
- 340
- References
- 248
- FWCI
- 23.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.